SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed ...

When I wrote about Nektar Therapeutics (NASDAQ: NKTR ) in April, a major focus of discussion was rezpegaldesleukin and trials of the drug in atopic dermatitis and alopecia areata. Since those trials won't produce data until 2025, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s D ...

Nektar Therapeutics (NKTR) incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents.In the year-ago quarter, the company reported an adjusted (excluding non-cash restructuring and impairment charges) loss of 18 cents.Total revenues remained flat year over year at $24.1 million. The reported figure beat the Zacks Consensus Estimate of $16 million.See the Zacks Earnings Calendar to stay ahead of market-making news. NKTR’s Q3 Results i ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Vivian Wu - Associate Director, Investor Relations and Corporate Affairs Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief Research and Development Officer Mary Tagliaferri - Chief Medical Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Julian Harrison - BTIG Jessica Fye - JPMorgan Andy Hsieh - William B ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value ...

Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO, November 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth qu ...

SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024.Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026."We made excellent progress this quarter advancing our I&I pipeline, ...

SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here Piper Sandler 36th Annual Healthcare Conference in New York, NY on Wednesday, December 4, 2024 at 1:00 p.m. Eastern Time / 4:00 p.m. Pacific Time – webcast link hereThe p ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home ...